Back to All Stocks

Eli Lilly and Company (LLY) Stock Forecast

AI-powered analysis with bull/bear cases, price targets, and news sentiment

Eli Lilly and Company (LLY) is a US-listed company in the Healthcare sector. The analysis below explains how investors typically evaluate a business of this type, the valuation assumptions our model applies to the sector, and how Eli Lilly and Company compares with its peers.

Sector: Healthcare · AI-assisted analysis, refreshed periodically. Not financial advice. See our disclaimer.

Eli Lilly and Company at a glance

Eli Lilly and Company trades under the ticker LLY on the NYSE and is classified in the Healthcare sector. This page brings together a live AI forecast, a discounted-cash-flow (DCF) valuation, and the fundamentals investors most often look at before taking a position.

Because Eli Lilly and Company sits in the Healthcare space, its results tend to move with the drivers specific to that sector. The valuation framework below reflects the growth, risk and discount-rate assumptions we apply to Healthcare companies rather than a one-size-fits-all model.

How we value a Healthcare stock like Eli Lilly and Company

Our 3-stage DCF model projects earnings for Eli Lilly and Company using sector-calibrated growth: roughly 10.0% EPS growth in the high-growth phase (years 1–5), fading to about 8.0% (years 6–10), and a long-run terminal growth of 3.5%.

Those cash flows are discounted at an estimated cost of equity of 8.6%, built from a 4.5% risk-free rate, a sector beta of 0.75, and an equity risk premium of 5.5% (CAPM). The output is an intrinsic value per share and a "margin of safety" versus the current $ market price — shown live in the Valuation tab.

A below-market beta suggests Eli Lilly and Company has historically been less volatile than the broader index, which usually points to a more defensive, lower-discount-rate profile.

Key things to watch with Eli Lilly and Company

Before relying on any single number, sanity-check the inputs: is the current P/E reasonable versus Eli Lilly and Company's own history and its Healthcare peers? Are earnings growing on a durable basis, or boosted by one-offs? How sensitive is the intrinsic value if growth comes in a couple of points below the sector assumption?

The AI Forecast tab adds qualitative colour — bull and bear cases, catalysts and risks — while the Valuation tab keeps the maths transparent. Treat both as a research starting point, not a recommendation.

Frequently asked questions about LLY

What sector does Eli Lilly and Company (LLY) belong to?

Eli Lilly and Company is classified in the Healthcare sector, alongside peers such as Intuitive Surgical Inc., Illumina Inc., Dexcom Inc.. Sector classification drives the growth and risk assumptions used in its DCF valuation.

How is Eli Lilly and Company's intrinsic value calculated?

We run a 3-stage discounted-cash-flow model using Healthcare-calibrated EPS growth (high-growth ~10.0%, fade ~8.0%, terminal 3.5%) discounted at an estimated cost of equity of 8.6%. The result is compared against the live $ price to give a margin of safety.

Is Eli Lilly and Company a good long-term investment?

That depends on your goals, risk tolerance and the price you pay. This page gives you the tools — intrinsic value, margin of safety, P/E context and an AI bull/bear view — to make that judgement, but it is educational analysis and not financial advice. Always do your own research or consult a licensed adviser.

How often is the Eli Lilly and Company analysis updated?

The live price and fundamentals refresh on each visit where data is available, while the AI commentary is regenerated periodically. The valuation recomputes from the latest price, so the margin of safety always reflects current market conditions.